The Business of Clinical Trials Is Booming. Private Equity Has Taken Notice.

Private equity firms have moved aggressively into the healthcare industry’s more hidden niches: They are pouring billions into the business of clinical drug trials.

Related Keywords

Louisiana ,United States ,United Kingdom ,Texas ,Boston ,Massachusetts ,California ,Houston ,Canada ,Lake Charles ,San Francisco ,Americans ,Scotland ,American ,Devora Torrence ,Linda Moore Schipani ,Michael Fenne ,Aaron Kesselheim ,Steven Deeks ,Nathalie Sohier ,Marcella Alsan ,Lyndon Fullen ,Danaka Williams ,Goldman Sach ,Johns Hopkins ,Mark Blumling ,Yashaswini Singh ,Cecil Nick ,Johns Hopkins University ,University Of California ,Harvard Kennedy School ,Linkedin ,Harvard Medical School ,Pfizer ,Astrazeneca ,Clinical Research Associates ,Headlands Research ,Johnson ,South Texas ,Provident Healthcare ,Centex Studies ,Pamplona Capital Management ,California San Francisco ,Private Equity Stakeholder Project ,